Vietnam's clinical laboratory sector is investing in higher-quality diagnostic testing as hospitals and laboratories strengthen quality assurance systems, pursue international accreditation and expand the use of advanced molecular diagnostics.
Although no dedicated valuation has been published for Vietnam's In Vitro Diagnostics (IVD) Quality Control market, industry analysis estimates the sector is currently worth US$18–24 million in 2025 and is expected to reach US$28–38 million by 2030.
IVD quality control is fundamental to ensuring laboratory test accuracy, consistency and regulatory compliance. It involves routine monitoring of diagnostic instruments, reagents and testing procedures to ensure that patient results remain reliable across every stage of laboratory operations.
The market includes:
- Third-party quality control materials
- Calibration verification products
- External Quality Assessment (EQA) programmes
- Proficiency testing
- Molecular diagnostic controls
- Hematology controls
- Clinical chemistry controls
- Immunoassay quality controls
- Laboratory quality management software
- Laboratory consulting and validation services
Several long-term trends are driving market expansion across Vietnam:
- Growing demand for laboratory accreditation under international standards such as ISO 15189.
- Expansion of molecular diagnostics and genetic testing.
- Rising adoption of laboratory automation.
- Increasing prevalence of infectious diseases and chronic illnesses requiring complex diagnostic testing.
- Greater regulatory focus on laboratory quality and patient safety.
- Growth in private diagnostic laboratory networks.
- Increasing use of digital laboratory information management systems (LIMS).
Vietnam's broader IVD market continues to expand steadily. According to IMARC Group, the country's In Vitro Diagnostics market reached US$349.3 million in 2025 and is projected to grow to US$503.6 million by 2034. Growth is being driven by rising healthcare awareness, increasing chronic and infectious disease testing, technological advances and expanding diagnostic infrastructure.
Clinical diagnostics is also seeing sustained investment. IMARC Group estimates Vietnam's Clinical Diagnostics market reached US$459.8 million in 2025 and is expected to grow to US$773.4 million by 2034, supported by increasing healthcare expenditure, wider adoption of digital health technologies and a stronger emphasis on preventive medicine. As testing volumes increase, laboratories are placing greater importance on robust quality control systems to maintain accuracy and regulatory compliance.
Molecular diagnostics represents one of the fastest-evolving areas of laboratory medicine. Vietnam's Molecular Diagnostics market reached US$108.5 million in 2025 and is forecast to grow to US$175.6 million by 2034. Technologies such as PCR, DNA sequencing and infectious disease testing require rigorous internal and external quality control processes, creating additional demand for specialised QC products and services.
Technology is transforming laboratory quality management. Modern quality control systems increasingly integrate cloud-based analytics, automated rule-based monitoring, artificial intelligence and real-time instrument performance tracking. These tools help laboratories identify analytical issues earlier, reduce repeat testing and support compliance with increasingly stringent quality standards. At the same time, external quality assessment schemes and digital quality management platforms are enabling laboratories to benchmark performance against national and international peers.
Leading suppliers including Bio-Rad Laboratories, Randox Laboratories, Thermo Fisher Scientific, Abbott, Roche Diagnostics, Siemens Healthineers, BioMérieux, LGC Clinical Diagnostics, Sysmex and Beckman Coulter continue to expand their portfolios of quality control materials, calibration products and laboratory quality management solutions.
As Vietnam continues to modernise its diagnostic infrastructure and strengthen laboratory quality standards, IVD quality control will become an increasingly strategic component of healthcare delivery. For manufacturers of quality control materials, laboratory automation systems, molecular diagnostics controls, digital quality management platforms and accreditation support services, Vietnam represents one of Southeast Asia's most attractive long-term growth opportunities.